ReviewActa pharmacologica Sinica2019
Brain activity of anandamide: a rewarding bliss?
Review in Acta pharmacologica Sinica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Endocannabinoids and Stress-Related Neurospsychiatric Disorders: A Systematic Review and Meta-Analysis of Basal Concentrations and Response to Acute Psychosocial Stress.Cannabis and cannabinoid research · 2024Pooled it
- Role of the CB2 Cannabinoid Receptor in the Regulation of Food Intake: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change.The International journal of eating disorders · 2026Trial
- PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder.Neuropsychopharmacology reports · 2026Observational
- Dynamic mechanism for subtype selectivity of endocannabinoids.The Journal of biological chemistry · 2026Article
- Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders.Translational psychiatry · 2026Review
- Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.Current topics in behavioral neurosciences · 2026Review
- A history of addiction through the six editions of Kandel'sFrontiers in behavioral neuroscience · 2026Review
- Elucidating the transcriptomic response of adult-derived mHypoA-2/12 mouse hypothalamic neuron cell line to cannabidiol (CBD) exposure.Journal of applied genetics · 2025Article
- From Synaptic Plasticity to Neurotoxicity: Endocannabinoid Influence on Addiction and Neurodegeneration.International journal of molecular sciences · 2025Review
- Cannabidiol (CBD) and Colorectal Tumorigenesis: Potential Dual Modulatory Roles via the Serotonergic Pathway.Current oncology (Toronto, Ont.) · 2025Review
- Recreational drugs repurposed for medicinal use-cannabis.CNS spectrums · 2025Review
- The Role of Endocannabinoids in Physiological Processes and Disease Pathology: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Nucleic Acid Conjugates: Unlocking Therapeutic Potential.ACS bio & med chem Au · 2025Review
- The Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test.Molecules (Basel, Switzerland) · 2025Article
- Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders.Current pharmaceutical design · 2025Review
- Practicing Emotional Self-awareness to Build Surgeon Resilience.Plastic and reconstructive surgery. Global open · 2025Article
- Cannabinoids-Multifunctional Compounds, Applications and Challenges-Mini Review.Molecules (Basel, Switzerland) · 2024Review
- Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volume.Translational psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Anandamide is a lipid mediator that acts as an endogenous ligand of CB1 receptors. These receptors are also the primary molecular target responsible for the pharmacological effects of Δ9-tetrahydrocannabinol, the psychoactive ingredient in Cannabis sativa. Several studies demonstrate that anandamide exerts an overall modulatory effect on the brain reward circuitry. Several reports suggest its involvement in the addiction-producing actions of other abused drugs, and it can also act as a behavioral reinforcer in animal models of drug abuse. Importantly, all these effects of anandamide appear to be potentiated by pharmacological inhibition of its metabolic degradation. Enhanced brain levels of anandamide after treatment with inhibitors of fatty acid amide hydrolase, the main enzyme responsible for its degradation, seem to affect the rewarding and reinforcing actions of many drugs of abuse. In this review, we will provide an overview from a preclinical perspective of the current state of knowledge regarding the behavioral pharmacology of anandamide, with a particular emphasis on its motivational/reinforcing properties. We will also discuss how modulation of anandamide levels through inhibition of enzymatic metabolic pathways could provide a basis for developing new pharmaco-therapeutic tools for the treatment of substance use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.